Release Date: February 25, 2019 Expiration Date: February 28, 2020 (subject to change)
CE for this activity will not be available after this date.
NEW FEATURE: Segment Review The presentation 'player' has a new feature in the menu called Segment Review. Once the presentation is complete, these links allow the learner to go directly to a specific topic area without having to move through the entire presentation a second time. This provides a faster review of those topics in the full presentation. Overview
Within this framework—the aging population, increasing prevalence of HF and comorbid conditions, polypharmacy and the concomitant challenges for patient management, and continuing poor prognosis—two recently approved pharmacotherapies could improve quality of life (QoL) and help reduce hospitalizations for patients with HF with reduced ejection fraction (HFrEF).
This activity is designed to inform nurse practitioners of patient selection criteria, dosing, and practical considerations for use of valsartan/sacubitril, an angiotensin receptor neprilysin inhibitor (ARNI), and ivabradine, a sinoatrial node inhibitor. It will also reinforce use of Guideline Directed Medical Therapy and assist the provider in devising strategies that promote treatment adherence. CE Credit Instructions
Read this activity description, including objectives and disclosures.
Complete the educational content completely:
Video Presentations: Watch all video presentations completely.
Review all additional materials provided (handouts, posttest reviews, all other downloadable resources).
After completing all content, go to Steps to Receive Credit to complete the posttest and evaluation to receive full AANP CE/Rx credit.
If other types of credit are offered, these options will be available after completing the activity evaluation.
60-days after the completion of this activity, respond to the post-activity survey invitation.
This is optional and does not affect the CE credit earned.
The survey is to help AANP weigh the outcomes of the activity. This improves future activities provided for all learners.
Describe the role of diagnostic and prognostic biomarker testing for individuals with, or at risk for, heart failure (HF).
Differentiate pharmaceutical treatment recommendations for HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF).
Review recommendations for newer classes of medications.
Identify strategies to improve adherence to treatment regimens.
Leslie Davis, PhD, RN, ANP-BC, FPCNA, FAHA, FAANP
Mary Ellen Roberts, DNP, RN, APNC, FAAN, FAANP
Disclosure This activity was planned in accordance with AANP Accreditation Standards and Policies. This activity is sponsored by an educational grant from Novartis. Dr. Davis discloses board membership with National Cardiovascular Data Registry Management. Dr. Roberts has no relevant affiliations to disclose.
This educational activity may contain opinions of the speakers from their personal experience. The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. Additional Information For questions about this online CE activity, or more information concerning the AANP CE Center, contact the AANP CE Center Manager at CECenter@aanp.org.
1 Contact Hour(s) of CE, All of which may be applied towards Pharmacology
Additional CE activities of interest
(OnDemand (MP4/MP3)) Diabetes and Cardiovascular Disease: The Shifting Paradigm of Individualized Care with SGLT-2s and GLP1-RAs